UCP1 and obesity disorder: The same molecule has also produced favourable results in rat models of type 2 diabetes (T2D) and obesity when administered by a nanochannel membrane device, providing a dramatic body weight reduction, normalization of cholesterol and glucose levels together with sustained expression of UCP1 in WAT [102].